AbbVie Acquires Nimble Therapeutics for $200M to Bolster Autoimmune Drug Portfolio Amidst Strategic Growth Moves

AbbVie's latest acquisition of Nimble Therapeutics for $200 million underscores its strategic focus on enhancing its autoimmune drug portfolio[1][2]. This purchase grants AbbVie access to Nimble's advanced peptide technology platform and a promising pipeline, including a preclinical IL23R inhibitor peptide aimed at treating conditions like psoriasis and inflammatory bowel disease[3][1]. By acquiring Nimble, AbbVie aims to diversify its growth strategies and mitigate expected market challenges such as the erosion faced by products like Skyrizi and Rinvoq[1]. This acquisition is part of AbbVie's ongoing efforts to sustain its leadership in immunology and bolster its long-term growth amid challenging market dynamics[3].